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MiR-23-TrxR1 as a novel 
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Thioredoxin reductase 1 (TrxR1) is a selenocysteine-containing protein involved in cellular redox 
homeostasis which is downregulated in skeletal muscle differentiation. Here we show that TrxR1 
decrease occurring during myogenesis is functionally involved in the coordination of this cellular 
process. Indeed, TrxR1 depletion reduces myoblasts growth by inducing an early myogenesis -related 
gene expression pattern which includes myogenin and Myf5 up-regulation and Cyclin D1 decrease. 
On the contrary, the overexpression of TrxR1 during differentiation delays myogenic process, by 
negatively affecting the expression of Myogenin and MyHC. Moreover, we found that miR-23a and miR-
23b - whose expression was increased in the early stage of C2C12 differentiation - are involved in the 
regulation of TrxR1 expression through their direct binding to the 3′ UTR of TrxR1 mRNA. Interestingly, 
the forced inhibition of miR-23a and miR-23b during C2C12 differentiation partially rescues TrxR1 levels 
and delays the expression of myogenic markers, suggesting the involvement of miR-23 in myogenesis 
via TrxR1 repression. Taken together, our results depict for the first time a novel molecular axis, which 
functionally acts in skeletal muscle differentiation through the modulation of TrxR1 by miR-23.
Mammalian Thioredoxin Reductase 1 (TrxR1) is a cytosolic selenocystein -containing protein that together with 
the Thioredoxins (Trx), mitochondrial Thioredoxin Reductase 2 (TrxR2) and NAPDH, constitute the antioxidant 
Thioredoxin system1. By using the NADPH as a source of reducing power, TrxR1 catalyzes the reduction of the 
active site disulphide in Trx1 which in turn supports the antioxidant cellular response in a variety of different 
ways2. The protective function of Trx-reduced activity includes the peroxiredoxin-dependent reduction of perox-
ides, the inhibitory effect on ASK-1-dependent apoptosis and the activation of specific redox-sensitive transcrip-
tion factors as NF-kB, AP-1 and Ref-13–7.
Independently from its antioxidant activity, the modulation of TrxR1 expression has been related to several 
cellular processes such as stress-induced premature senescence, cell-sufficient growth, embryonic proliferation, 
DNA replication and malignant transformation8–11, thus identifying a role for TrxR1 in cancer progression, and 
suggesting a putative functional involvement in many other diseases.
TrxR1 expression has been detected in a wide range of different tissues including skeletal muscle, but its func-
tion in processes related to muscle biology is still unknown.
Skeletal muscle differentiation is a finely regulated process where mononucleated myoblasts irreversibly with-
draw from cell cycle, reach an early step of differentiation (monocytes), and finally fuse into multinucleated 
myotubes, which are the precursors of mature muscle fibers (terminal differentiation)12, 13.
This process is orchestrated by the spatio-temporal-regulated expression and activation of the myogenic reg-
ulatory factors (MRFs) including MyoD, Myf5, Myogenin and MRF4, which are specific transcription factors 
belonging to the basic helix-loop helix family. Together with other general or muscle-specific factors, such as 
the myocyte enhancer factor 2 (Mef-2), MRFs coordinate muscle development by activating and repressing the 
expression of a genetic network controlling myogenesis12. MyoD and Myf5 are required for the specific commit-
ment to the myogenic lineage, whereas Myogenin is involved at the early step of differentiation12.
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MicroRNAs are a class of small (21–25 nucleotides) non coding RNAs that regulate gene expression at the 
post-transcriptional level14. Specifically, a single microRNA can inhibit the expression of hundreds of messenger 
RNAs (mRNAs) by direct pairing between its 5′ end (seed sequence) and complementary sequences on these 
mRNA targets, usually located in the 3′UTRs15. In the last years, a broad number of microRNAs has been found 
to play a crucial role in skeletal muscle myogenesis16. The functional contribution of most of them in regulation of 
muscle differentiation-related processes has been determined; particularly for the “myomiRs”, a set of microRNAs 
exclusively or preferentially expressed in striated muscle16–18. Beyond myomiRs, other ubiquitously expressed 
microRNAs appear to be involved in the regulation of muscle development by modulating the expression of sev-
eral protein targets controlling myogenesis-related cellular processes such as proliferation, migration, epigenetic 
regulation and cell cycle coordination16, 19–22.
miRs-23 family consists of two isomiRs, miR-23a and miR-23b, belonging to the miR-23~27~24 clusters23. 
Because of their ability to regulate proliferation, differentiation and apoptosis in different cell types, the microRNA 
members of these clusters have been associated with a wide range of human diseases23, 24. The expression of these 
microRNAs has been also detected in skeletal muscle cells where they take part to several muscle-related pro-
cesses22, 25, 26. It has been observed that miR-27b and miR-24 function as positive regulators of skeletal muscle 
differentiation; in particular, miR-27b ensures the entry of satellite cells into the myogenic program by regulating 
Pax3 expression22, whereas miR-24 promotes terminal differentiation through the TGF-β-mediated pathway25. 
In contrast, the functional role of miR-23a in muscle cells appears related to the protection against skeletal muscle 
atrophy26.
In this paper we describe for the first time that the negative modulation of TrxR1 occurring during skeletal 
muscle differentiation represents a key step in the establishment of this cellular process, because of its involve-
ment in the transition from proliferating myoblasts to terminally differentiated myotubes. Moreover, we docu-
ment the regulation of TrxR1 expression by miR-23a and miR-23b through the direct binding to its 3′ UTR. Our 
findings suggest a novel miRNA-based regulatory network acting on skeletal muscle differentiation.
Results
TrxR1 is highly expressed in skeletal muscle tissues and its expression is downregulated during 
myogenesis. TrxR1 protein levels were widely detected by western blot analysis in total lysates of several 
murine skeletal muscle tissues as gastrocnemius, extensor digitorum longus and soleus, as well as in C2C12 cells, 
a well-established cellular model of murine myoblasts that can recapitulate in vitro the process of skeletal muscle 
differentiation (Supplementary Fig. S1a and Fig. 1a).
In searching for the putative role of TrxR1 in skeletal muscle differentiation, we decided to monitor its 
expression levels in C2C12 cells under growth conditions and at different days of differentiation ranging from 
Figure 1. TrxR1 is downregulated during skeletal muscle differentiation. (a) Representative image of C2C12 
myoblasts differentiation process. Growth medium (GM) is maintained in proliferation conditions (Prol) 
until 90% confluency. Pictures were taken respectively at 0, 1, 2, 3 and 5 days after switching to differentiation 
media (DM). (b) Western blot analysis showing the TrxR1 protein contents in C2C12 cells cultivated in 
GM and DM (1, 2, 3, 5 days) conditions. Antibodies against Myogenin, p38, p-p38 and MyHC were used 
to monitor myogenesis process, whereas β-actin was employed as a housekeeping loading control. (c) 
Relative quantification of TrxR1 protein expression normalized to β-actin levels of western blots in figure 
b. The TrxR1/β-actin ratio in GM conditions is set = 1. Results are represented as mean ± SEM of three 
independent experiments. (d) Images (10x magnification) of murine satellite cells in proliferation (GM) and 
5 days after switching to differentiation media (DM). (e) Representative image (63x magnification) of the 
immunofluorescence analysis showing TrxR1 expression in satellite cells and in (f) myotubes originated from 
them. Multinucleated myotubes are positive for MyHC and DAPI staining was used to detect nuclei.
www.nature.com/scientificreports/
3SCIENtIFIC RepoRts | 7: 7219  | DOI:10.1038/s41598-017-07575-0
1 to 5. As shown in Fig. 1b, a marked reduction of TrxR1 protein was observed by western blot analysis during 
myogenic differentiation of C2C12 cells. Concurrently, myogenic markers of differentiation such as Myogenin, 
phospho-p38 and MyHC were found to be upregulated, and myotube formation was observed in culture plates 
between the 3rd and 5th differentiation day (Fig. 1a and b). Down-regulation of TrxR1 protein became signifi-
cant from day 2 of differentiation (GM vs D2 p = 0.0013; GM vs D3 p = 0.0005; GM vs D5 p = 0.0039) (Fig. 1c). 
Similar results were obtained by using immunofluorescence analysis. The detection of TrxR1 signal was evident 
at GM and D0, whereas at D2 and D3 the expression was lower. According to western blot analysis, a recovery of 
the signal was observed in at least a part of terminally differentiated myotubes (D5) (Supplementary Fig. S1b). A 
TrxR1 tendency to decrease was observed also in an ex vivo model of muscle myogenesis. To this purpose, mouse 
satellite cells were purified from hind limb muscles and induced to differentiate in vitro (Fig. 1d). As shown in 
Fig. 1e, TrxR1 expression is generally marked in proliferating murine satellite cells (Fig. 1e) and lower in the dif-
ferentiating myotubes originated from the same cells following in vitro differentiation (Fig. 1f). Interestingly the 
ratio between the oxidative/reduced status of Trx-1, the major target of the TrxR1- mediated antioxidant activity, 
was unchanged during C2C12 myogenesis, suggesting a Trx-1-independent role of TrxR1 in this specific biolog-
ical process (Supplementary Fig. S2).
To check if TrxR1 has a functional role in myogenesis, we decided to inhibit its expression in C2C12 cells by an 
siRNA-mediated strategy and analyse the consequences on differentiation process. As shown in Supplementary 
Fig. 4a, TrxR1 depletion resulted in a dramatic decrease of C2C12 myogenic rate. Indeed, TrxR1 siRNA trans-
fected myoblasts, submitted to differentiate, exhibited a significant reduction of protein levels of myogenin at D2 
(p = 0.031) and MyHC at D3 (p = 0.0012) (Supplementary Fig. 4b). Consequently, this effect resulted in a broad 
impairment of myotubes formation as monitored by the significant decrease in their fusion index (scr siRNA: 
33.2 ± 3.5, TrxR1 siRNA: 8.2 ± 4; p = 0.0075) (Supplementary Fig. 4c and d).
Thus, TrxR1 protein appears to be pivotal in skeletal muscle myogenesis and the fluctuations of its expression 
levels could have a crucial role in regulating this specific biological process.
TrxR1 knockdown induces an early myogenesis-related gene expression pattern and reduces 
C2C12 cell growth, whereas ectopic overexpression delays C2C12 muscle differentiation. The 
differential expression pattern of TrxR1 during muscle myogenesis prompted us to explore its putative functional 
role in the switch between proliferation and differentiation. Firstly, using an siRNA-mediated strategy we inhib-
ited TrxR1 expression in myoblasts under growth conditions, and then examined the expression of genes related 
to the early steps of the myogenic program. As shown in western blots in Fig. 2a, 48 hours after siRNA transfec-
tion, TrxR1-depleted cells exhibited lower Cyclin D1 and higher Myf5 protein levels with respect to the controls 
(scr siRNA) (Fig. 2a), whereas no change in p21 was observed (Fig. 2a). In parallel, we performed a RT-qPCR 
analysis for measuring the expression of Myf5, Cyclin D1, p21 and Myogenin mRNAs in TrxR1 siRNA versus 
control cells. Results obtained showed a significant increase of Myf5 at both time analysed (36 h: 1.6 ± 0.36 fold 
p = 0.0196; 48 h: 1.44 ± 0.2 fold p = 0.021) and of Myogenin at 48 hours (1.49 ± 0.18 fold p = 0.028) after siRNA 
TrxR1 transfection (Fig. 2b).
Moreover, p21 mRNA levels were only slightly up-regulated in TrxR1 depleted cells (Fig. 2b), whereas those 
of Cyclin D1 were unchanged, suggesting, as reported by other groups (Diehl et al., 1998, Alteri et al., 2013) the 
putative involvement of a post-transcriptional control taking part in regulation of the protein contents.
Thus, inhibition of the expression of TrxR1 appears to generate a specific gene expression pattern strictly 
related to that typically shown by C2C12 myoblasts at the early stage of myogenesis, during the transition between 
their proliferative to terminal differentiation status.
In agreement with this, TrxR1-depleted cells exhibited a reduced growth rate with respect to those observed 
in scrambled siRNA-transfected and untransfected (mock) cells. Indeed, as shown in Fig. 2d, the OD values 
measured by MTS assay in TrxR1 siRNA-transfected myoblasts were lower than those of the other experimental 
groups, reaching a significant decrease at 72 hours (mock: 1.94 ± 0.03, scr siRNA: 1.88 ± 0.044, TrxR1 siRNA: 
1.6 ± 0.04; scr siRNA vs TrxR1 siRNA p = 0.0033) (Fig. 2c). Concomitantly, a reduced cellular confluence was 
observed in TrxR1 depleted cells (Fig. 2d). Moreover cell cycle phase distribution analysis showed that myoblasts 
transfected with TrxR1 siRNA had a significant decrease in S phase population as compared to mock and scr 
siRNA- transfected cells (mock: 23.6 ± 1.25, scr siRNA: 23.4 ± 1.4, TrxR1 siRNA: 17.3 ± 2.3; scr siRNA vs TrxR1 
siRNA p = 0,045), with a concomitant increase of the G1 portion (Fig. 2e).
Taken together, these results suggest that TrxR1 decrease during myogenesis may be functionally involved in 
the coordination of this process, by contributing to the establishment of the genetic network linked to the transi-
tion from proliferating myoblasts to terminally differentiated myotubes.
To support this hypothesis, we decided to test whether the rescue of TrxR1 expression levels in C2C12 cells 
under differentiation conditions could negatively affect their myogenic rate. Therefore, a TrxR1 expression vector 
(p-TrxR1) or an empty vector (pcDNA3.1) were transfected in C2C12 myoblasts induced to differentiate and the 
expression of myogenic markers was monitored after 48 (D2) and 72 (D3) hours. As shown in the western blot 
in Fig. 3a and b, C2C12 cells transduced with p-TrxR1 exhibited an increase of TrxR1 protein levels with respect 
to control or pcDNA3.1 cultures, ranging from 2.3 to 1.7 fold, at D2 (p = 0.035) and D3 respectively (Fig. 3a 
and b). The ectopic overexpression of TrxR1 was related to a significant reduction of Myogenin (pcDNA3.1 vs 
p-TrxR1: 1.1 ± 0.1 vs 0.6 ± 0.07; p = 0.011) and MyHC expression (pcDNA3.1 vs p-TrxR1: 1.1 ± 0.1 vs 0.45 ± 0.07; 
p = 0.0168) measured on the 3rd day of differentiation and/or transfection (Fig. 3c and d). This effect was con-
comitant with a reduction of myotube formation in TrxR1-transfected cultures as monitored by both, immu-
nofluorescence analysis for MyHC and the related fusion index (p = 0,017) (Fig. 3e and f). These results clearly 
demonstrate that the rescue of TrxR1 expression levels under differentiation conditions is sufficient to delay the 
process of C2C12 myogenesis.
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Figure 2. The siRNA-mediated TrxR1 inhibition reduces C2C12 cell growth and induces an early myogenesis-
related gene expression pattern. C2C12 myoblasts were transfected with a scramble siRNA (scr siRNA) or a 
siRNA against TrxR1 sequence (TrxR1 siRNA) and cultivated in GM for 24–72 hours. (a) Western blot analysis 
showing the protein levels of TrxR1, Cyclin D1, p21 and Myf5 at 36 and 48 hours after transfection and the 
histogram relative to quantification of Cyclin D1 and Myf5 protein levels, represented as mean ± SEM of 
five different western blot as in panel a. The TrxR1/β-actin ratio of scr siRNA C2C12 is set = 1. (b) RT-qPCR 
analysis showing the mRNA expression levels of Myf5, Cyclin D1, p21 and Myogenin at 36 and 48 hours after 
transfection. Cyclophilin A mRNA was used to normalize the relative amount of each mRNA analysed. Results 
are represented as mean ± SEM of at least three different experiments. (c) MTS assay measured at 24, 48 and 
72 hours after transfection. (d) Image (20x) showing cellular confluence at 72 hours. (e) Cytofluorimetric 
analysis showing cell cycle phase distribution.
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TrxR1 3′UTR harbours two putative binding sites for miR-23a and miR-23b and TrxR1 expres-
sion during the early C2C12 differentiation is inversely related to that of both those microR-
NAs. The differential pattern of TrxR1 expression observed in cycling myoblasts versus myotubes prompted 
us to investigate the molecular regulatory mechanism driving its expression in this specific biological process.
To do this, we measured the levels of TrxR1 mRNA in C2C12 cells kept in GM or after the switch in DM and 
collected at different days of differentiation. As shown in Fig. 4a, the results obtained by RT-qPCR clearly showed 
a 50% decrease of TrxR1 mRNA expression at D1 and D2 and about 40–45% decrease at D3. Interestingly, a 
smaller reduction was observed in the time period starting from D3, becoming non significant at D5 (Fig. 4a). 
This specific pattern of expression was also confirmed during the progression into myogenesis of ex vivo satellite 
cells cultivated in proliferative (GM) versus differentiation (DM) conditions (Fig. 4b).
One of the mechanisms accounting for the negative regulation of an mRNA levels is that exerted through 
microRNAs27. Given this, we performed a bioinformatic search for putative microRNA binding sites in the 3′ 
UTR of TrxR1, which is known to be involved in the rapid turnover of TrxR1 mRNA, leading to the deregulation 
of its protein product28.
This analysis, carried out by using Targetscan tool (www.targetscan.org), revealed the presence of two putative 
conserved binding sites for miR-23a and/or miR-23b located at nucleotides 973–979 (site 1) and 1622–1629 (site 
2) of TrxR1 3′UTR (Fig. 4c).
To look for a putative relationship linking TrxR1 and miR-23 during myogenesis, we measured the expression 
levels of both miR-23a and miR-23b in C2C12 myoblasts under GM conditions and at different time points of 
differentiation. As shown in Fig. 4d, a significant increase of both these microRNAs was observed by comparing 
GM with DM conditions. In particular, a change ranging from 2.5 to 4.5 fold was measured in the early days of 
differentiation. Interestingly, on the 5th day of differentiation (D5), miR-23b maintained an increasing trend 
whereas miR-23a did not (Fig. 4d). Thus, the inverse relationship between the expression of these microRNAs and 
that of TrxR1 at both protein and mRNA levels observed during early C2C12 myogenesis, suggested us a putative 
role for miR-23 in the regulation of TrxR1.
miR-23a and miR-23b negatively affect TrxR1 expression levels by directly binding to its 
3′UTR. To experimentally validate the putative correlation between miR-23 and TrxR1, we performed experi-
ments to modulate miR-23a and miR-23b in C2C12 myoblasts, and measured the effects on TrxR1 expression lev-
els. We transfected synthetic double-stranded RNA molecules designed to specifically mimic endogenous mature 
miR-23a or miR-23b. Initially, we monitored by RT-qPCR the efficiency of each one of these molecules in driving 
the specific over-expression of the corresponding microRNA. Transfections with a synthetic miR-23a increased 
the specific expression of miR-23a without affecting miR-23b levels. In contrast, C2C12 cells transduced with a 
Figure 3. TrxR1 overexpression delays C2C12 differentiation. C2C12 were transfected or not (mock) with 
p-TrxR1 or the empty vector pcDNA3.1 and analysed at 48 (D2) and 72 hours (D3) from differentiation 
induction. (a) Representative image of the western blot analysis showing the protein expression of TrxR1, 
Myogenin, MyHC and β-actin. The amount of TrxR1 (b), Myogenin (c) and MyHC (d) in each sample was 
calculated by normalizing to β-actin protein levels. Results are represented as mean ± SEM of at least three 
different experiments. The ratio of mock sample was set = 1. (e) Representative image (20x magnification) of the 
immunofluorescence analysis showing MyHC expression at D3 of differentiation. DAPI staining was used to 
detect nuclei. (f) Fusion index relative to D3 calculated in at least five random microscopic fields.
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synthetic miR-23b displayed high levels of miR-23b but not of miR-23a (Fig. 5a). As shown in Fig. 5b, a robust 
and significant down-regulation of TrxR1 protein was observed at 48 (miR-23a: p = 0.0009 miR-23b: p = 0.0025) 
and 72 (miR-23a: p = 0.0012 miR-23b: p = 0.0035) hours after transfections with mimics of miR-23a or miR-23b 
(Fig. 5b and c). Under the same conditions, the levels of TrxR1 mRNA were found to be negatively modulated 
by the ectopic expression of these microRNAs (Supplementary Fig. S5a). To explore if the miR-23-mediated 
downregulation of TrxR1 was able to negatively affect C2C12 growth, we performed an MTS assay in miR-23a, 
miR-23b and scr miR transfected myoblasts. As shown in Supplementary Fig. S5b, a significant reduction of OD 
was observed in miR-23a and b-transfected versus control (src miR) cells after 72 hours (scr miR vs miR-23a 
p = 0.0062; scr miR vs miR-23b p = 0.0094). Thus, the resulting effect was in line with that obtained by the trans-
fection of TrxR1 siRNA (see Fig. 2c), strengthening the hypothesis of the connection between miR-23 and TrxR1 
and the consequences in cellular properties due to TrxR1 modulation.
To prove that the observed modulation of TrxR1 was due to a direct action of miR-23 on TrxR1 3′UTR, we 
generated a reporter construct by cloning the TrxR1 3′UTR downstream of the renilla luciferase reporter gene in 
psicheck plasmid (psi-wt) (Fig. 5d). Then, a luciferase assay was performed by measuring the renilla/firefly (Luc) 
activity in C2C12 cells transfected with psi-wt together with either a scrambled microRNA (scr miR) or mimic 
miR-23a, miR-23b or miR-23a plus miR-23b (miR-23a-b) (Fig. 5e).
As shown in Fig. 5e, transfections with either miR-23a or miR-23b alone, or miR-23a-b, were all able to induce 
more than a 2 fold decrease of luciferase activity levels with respect to those observed in scr miR transfections 
(Fig. 5e).
The same experiment was also performed by transfecting cells with a construct harbouring a 3′UTR mutated 
in miRNA-23 binding sites (psi mut1-2) (Fig. 5d). The effect of miR-23a, miR-23b and miR-23a-b mimics on 
luciferase activity was completely abolished in cells transduced with psi mut 1-2, suggesting a direct role of these 
sites in mediating the miR-23- dependent TrxR1 regulation (Fig. 5e).
LNA-mediated inhibition of miRs-23 counteracts the TrxR1 downregulation in C2C12 differen-
tiation and negatively affects Myogenin and MyHC expression. To identify a functional role in the 
process of muscle differentiation to the molecular axis linking miR-23 to TrxR1, we decided to transfect C2C12 
myoblasts with a specific antisense inhibitor (LNA) of both miR-23a and miR-23b, and determine whether this 
would prevent TrxR1 downregulation during differentiation as well as in counteracting myogenic program.
Figure 4. miR-23 is a putative regulator of TrxR1 expression during skeletal muscle differentiation. (a) RT-
qPCR analysis showing the relative expression of TrxR1 mRNA in proliferating (GM) versus differentiating 
(DM) C2C12 cells collected at 1, 2, 3 and 5 days. Data were normalised to Cyclophilin A expression and 
represented as mean ± SEM of three independent experiments. (b) Relative expression of TrxR1 mRNA in 
proliferating (GM) versus differentiating (DM) satellite cells, measured by RT-qPCR and normalized to GAPDH 
expression. (c) Putative miR-23a and b binding sites in the 3′ UTR of TrxR1 mRNA. (d) RT-qPCR analysis 
displaying miR-23a andmiR-23b expression (normalized to U6 snoRNA) in C2C12 proliferating (GM) versus 
differentiating (DM) cells. Data are exposed as mean ± SEM of three experiments. The normalised GM values of 
each miRNA were set = 1.
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As shown in Fig. 6a, myoblasts transduced with miRs-23 LNA exhibited higher levels of TrxR1 protein than 
control cells transfected with a scramble LNA. This effect was particularly evident on the 3rd day of differentiation 
(D3) as shown in Fig. 6b (scr LNA: 1.06 ± 0.09 vs miRs-23 LNA: 1.5 ± 0.12; p = 0.048). In order to understand if 
the resulted up-regulation of TrxR1 by miRs-23 LNA was effective in delaying C2C12 myogenesis, we monitored 
the expression of Myogenin and MyHC as markers of terminal differentiation. As expected, western blot anal-
ysis performed at D2 and D3, revealed a slight but reproducible downregulation of Myogenin at D2 (scr LNA: 
1.18 ± 0.1 vs miRs-23 LNA: 0.7 ± 0.09; p = 0.014 (Fig. 6a and b) and MyHC at D3 (scr LNA: 1.1 ± 0.06 vs miRs-23 
LNA: 0.84 ± 0.03; p = 0.016) (Fig. 6a and b) in cell cultures transfected with miRs-23 LNA.
These results prompted us to investigate about a chance of delayed myogenesis due to the observed downregu-
lation of myogenin and MyHC. The fusion index measured in myotubes cultures with scr LNA and miRs-23 LNA 
(Fig. 6c) did not show any significant change, although a tendency to decrease in miRs-23 LNA was appreciated 
(Fig. 6d).
Taken together, these results support a role of miR-23-dependent downregulation of TrxR1 in the regulation 
of myogenic markers and its putative involvement in the process of skeletal muscle differentiation.
Discussion
Although a series of findings suggest a putative role of TrxR1 in muscle myogenesis, its functional involvement 
in this cellular process has never been addressed until now. In particular, it is intriguing that TrxR1 expression 
levels are down-regulated during the in vitro differentiation of muscle myoblasts as well as of satellite cells29, 30 
(see Fig. 1).
In this manuscript, we describe for the first time that the antioxidant enzyme TrxR1 plays a functional role in 
skeletal myogenesis, and we identify a miR-23-dependent post-transcriptional regulatory mechanism acting on 
muscle differentiation through the direct modulation of TrxR1 expression levels.
Our findings indicate that the reduced expression of TrxR1 observed during the differentiation of C2C12 myo-
blasts and mouse satellite cells seems to represent a key step in the this finely regulated cellular process. To prove 
this, we undertook a series of experiments demonstrating that: a) inhibition of TrxR1 in myoblasts generates a 
pro-differentiation stimuli (Fig. 2), and b) overexpression of TrxR1 is able to delay C2C12 differentiation (Fig. 3). 
In myogenesis, the processes of proliferation and terminal differentiation are mutually exclusive and it is well 
known that these are finely coordinated by molecules controlling cell cycle exit as well as induction of MRFs31. 
Consistent with this, we found that TrxR1-depleted cycling myoblasts show a reduction of Cyclin D1 protein 
levels, a well-known inhibitor of muscle myogenesis32 and a concomitant enhancement of Myf5. As reported 
by Wang and colleagues, Myf5 is up-regulated at the early stage of C2C12 differentiation and its forced repres-
sion negatively affects the myogenic rate of these cells33. Additionally, we also observed an increase in Myogenin 
Figure 5. miR-23 overexpression negatively regulates TrxR1 levels by targeting its 3′UTR. C2C12 myoblasts 
were transfected with mimic miR-23a, mimic miR-23b or a scramble miR (scr miR). (a) RT-qPCR showing 
the expression of miR-23a and miR-23b 48 hours after transfection. (b) Representative western blot displaying 
TrxR1 protein levels at 48 and 72 hours after transfection. The lysates originated by C2C12 transfected with 
an siRNA against the TrxR1 mRNA sequence (TrxR1 siRNA) were loaded as positive control of TrxR1 
downregulation. (c) Quantification of panel b performed on three independent experiments. TrxR1 proteins 
levels were normalized to β-actin and the value of scr miR was arbitrarily set = 1. (d) A schematic view of the 
reporter construct generated by cloning the 3′UTR sequence of TrxR1 mRNA in psicheck vector downstream 
of renilla luciferase cDNA (psi-wt). Site-specific mutagenesis was performed to generate the reporter construct 
harbouring the 3′UTR mutated in miR-23 binding sites 1 and 2 (psi mut1-2). (e) Histograms showing the 
relative amount of Renilla/Ffly ratio measured in lysates of C2C12 cells transfected with psi wt, psi mut1 or psi 
mut1-2 in the presence of scr miR, mimic miR-23a, mimic miR-23b or both (miR-23a-b). The experiment was 
performed three times. Each biological assay was done in triplicate.
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mRNA levels which is recognized as one of the master regulators of myogenesis, activated in early differentia-
tion12. Thus, the downregulation of TrxR1 could be crucial in the establishment of such a gene expression pattern 
promoting the withdrawal from cell cycle and the entry of myoblasts into the myogenic process. Moreover, this 
molecular event appears to be necessary for efficient muscle differentiation, because, as clearly shown in Fig. 3, a 
forced increase of TrxR1 protein levels in myoblasts, strongly reduces their myogenic ability. Collectively our data 
underline the functional relevance of the switch in TrxR1 content in the differentiation process. Indeed, even the 
disruption of this physiological expression pattern by siRNA interference during the early phases of differentia-
tion, strongly impair C2C12 myogenesis (see Supplementary Fig. 4). Thus, the establishment of such expression 
pattern seems to be critical for the right execution of this biological process. Accordingly, it could be reasonable to 
hypothesized that only TrxR1 highly-expressive myoblasts or myocytes undergo myogenesis through a fine and 
temporal mechanism of TrxR1 negative modulation, suggesting the pivotal role of this protein and its fluctuations 
in muscle development.
The mechanism of action by which TrxR1 exerts its role in skeletal muscle differentiation is still poorly under-
stood. To look for a putative involvement of TrxR1 in the ASK-1 dependent-p-38 MAPK activation by its main 
target, Trx1, we attempted to correlate the physiological TrxR1 downregulation to the oxidation of Trx1, but 
we did not observe any alteration of the Trx1 oxidative status in C2C12 during differentiation (Supplementary 
Fig. S2). Thus, as already proposed by Arner and colleagues34 TrxR1 may exert its function in a Trx1 -independent 
manner. Moreover, we may even speculate whether this is a redox-independent role, a conclusion that may be 
supported by the evidence linking the redox function of the antioxidant enzymes in muscle differentiation to the 
overall tendency in increasing their expression levels30, 35.
However, our main findings highlight the functional importance of a decrease of TrxR1 in skeletal muscle 
differentiation.
In this context, the identification of miR-23 as a new molecular regulator of TrxR1 expression and its role dur-
ing skeletal muscle differentiation is of great importance. In agreement with microRNA biology, we found that the 
regulation of TrxR1 expression is mediated by the direct binding of miR-23a and miR-23b on its 3′UTR. Results 
obtained by our experimental approach (i.e. overexpression of miRNA mimics and evaluation of their effect on 
TrxR1 expression levels and 3′UTR activity of Fig. 5) clearly validate this molecular relationship and point to a 
post-transcriptional regulatory mechanism acting on TrxR1 3′ UTR. In agreement with this, published studies 
have described the pivotal role of TrxR1 3′ UTR in the regulation of this protein36. In particular there are reports 
that 3′ UTR of TrxR1 contains several AUUUA motifs (AU-rich-elements), also recognized as AREs, which are 
functionally involved in its mRNA turnover28, 36. Moreover, our in silico analysis revealed that a putative consen-
sus sequence for the binding of CPEB (cytoplasmic polyadenylation element binding protein) is embedded in 
this 3′ UTR (data not shown). Thus, the newly identified miR-23 mediated regulatory mechanism is likely to take 
part, with other classes of molecules (i.e CPEB, or AREs binding proteins) in the complex post-transcriptional 
Figure 6. miRs-23 LNA transfection negatively affects Myogenin and MyHC expression and counteracts 
the downregulation of TrxR1 during C2C12 differentiation. C2C12 were transfected or not (mock) with 
miRs-23 LNA or a scramble LNA (scr LNA) and analysed at 48 (D2) and 72 hours (D3) from differentiation 
induction. (a) Representative image of the western blot analysis showing the protein expression of TrxR1, 
MyHC, Myogenin and β-actin. (b) The amount of TrxR1, MyHC and Myogenin in each sample was calculated 
by normalizing to β-actin protein levels. Results are represented as mean ± SEM of at least three different 
experiments. The ratio of mock sample was set = 1. (c) Representative image (20x magnification) of the 
immunofluorescence analysis showing MyHC expression at D3 of differentiation and the related fusion index 
(d). DAPI staining was used to detect nuclei.
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regulation acting on TrxR1 expression via its 3′UTR. Moreover, given the relevance of TrxR1 in several human 
diseases including cancer37, 38, the identification of a novel mechanism which can modulate its expression may 
open new interesting perspectives.
The molecular axis linking miR-23 to TrxR1 appears to be active in the early phases of myogenic process. 
Indeed, the inverse correlation between the expression of these miRs and TrxR1 is maintained up to D2 of differ-
entiation. By D3 to D5 the displayed pattern appears to be incongruent: miR-23a remains unchanged, miR-23b 
undergoes a strong increase and TrxR1 tends to rise, suggesting a loss of the regulatory circuitry. This specific 
readjustment could reflect the well known peculiarity of miR-23a and b in differentially changing their pattern 
of expression as well as their target activity39, thus suggesting divergent role at the late differentiation. However, 
the, role of this molecular axis in myogenesis, firstly suggested by the inverse correlation between the expres-
sion levels of miR-23a and miR-23b and those of TrxR1 observed during C2C12 differentiation, is supported 
by results obtained from experiments on the specific inhibition of miR-23. As shown in Fig. 6, the rescue of the 
TrxR1 levels in myoblasts transfected with a miRs-23 LNA and switched to differentiation conditions, corre-
lates to a slight but reproducible reduction of myogenic markers, thus suggesting the involvement of miR-23 in 
that process via TrxR1 modulation, and consequently strengthening the role of TrxR1 as negative regulator of 
muscle differentiation. Indeed, even a partial rescue of TrxR1 levels during differentiation is able to affect both 
Myogenin and MyHC proteins Probably because of their slight modulation, the consequent effect on muscle dif-
ferentiation seems to be not morphologically relevant although a reduced trend in the fusion index was observed. 
Interestingly, the failure of a full restauration of TrxR1 levels could suggest the putative involvement of other 
regulatory mechanisms acting together with miR-23. Moreover, we cannot exclude methodological limits, as for 
example those due to the transient transfection, that probably does not provide a high transduction efficiency.
The known miR-23 biology appears support our findings in multiple ways. As reported by Wada and col-
leagues, miR-23 sustains skeletal muscle hypertrophy through downregulation of MAFbx/Atrogen126, and blocks 
cell cycle progression in endothelial cells40. In addition a series of enzymes such as Peroxiredoxin 341 and mito-
chondrial glutaminase42 associated, like TrxR1, to redox homeostasis, have been shown to be direct targets of 
miR-23 in non-muscle cells.
Thus, our results extend those findings by including miR-23a and miR-23b in the wide class of muscle differ-
entiation noncoding RNAs, where even miR-27 and miR-24 which are clustered together with miR-23, take part. 
As already reported, the coordinated association of microRNAs from the same cluster toward a specific function 
is challenging23, 43 and, in this specific context, could prove to be effective in enhancing myogenesis functionality.
In conclusion, we have identified a novel molecular axis which functionally acts in skeletal muscle myogenesis 
through the modulation of the antioxidant enzyme TrxR1 by miR-23. These results might be useful in the field of 
muscular diseases or in other TrxR1-linked pathological conditions such as carcinogenesis.
Methods
Cell preparation and FACS isolation. Hind limb muscles from C57/BL6 wild type mice (Charles River 
Laboratories) were minced and digested in PBS (Sigma) containing 0.1% BSA, 300 µg/ml Collagenase A (Roche), 
0.24 U/ml Dispase I (Roche), 2 μg/ml DNase I (Roche), 50 μM CaCl2 and 1 mM MgCl2 for 60 min at 37 °C under 
constant agitation. For fluorescence-activated cell sorting, digested muscle cells were stained with primary anti-
bodies (1:50) CD3-eFluor450 (eBioscience), CD45-eFluor450 (eBioscience), Ter119-eFluor450 (eBioscience), 
Sca-1-FITC (BD Pharmingen), and α7integrin-APC (AbLab) for 30 min at RT. Cells were finally washed and 
resuspended in Running Buffer (PBS, 0.1% Sodium Azide, 0.2% FBS). Flow cytometry analysis and cell sorting 
were performed on a DAKO-Cytomation MoFlo High Speed Sorter.
Muscle satellite cells (SCs) were isolated as Ter119−/CD45−/CD31−/α7-integrin+/Sca-1− cells. 
Fibro-adipogenic progenitors (FAPs cells) were isolated as Ter119−/CD45−/CD31−/α7-integrin−/Sca-1+ cells, 
as previously described44.
Cell cultures. C2C12 mouse myoblasts were cultivated in DMEM/high glucose supplemented with FBS (10–
15%) (growth media; GM) as previously described45. To induce myogenic differentiation, cells reaching a conflu-
ence of about 75–80% were switched in FBS-low (2%) DMEM media (Differentiation media; DM) and collected 
and/or analyzed after 24 (D1), 48 (D2), 72 (D3) and 120 (D5) hours.
1 × 104 freshly sorted SCs were plated on the 0.1% gelatin-coated bottom of a 24-well plate, while 0.5 × 104 
FAPs cells were plated on the upper insert. Transwell co-cultures were maintained in growth medium (GM) 
(DMEM GIBCO containing 20% FBS, 10% horse serum and 1% chicken embryo extract) for 7 days and then 
harvested for analyses (Immunofluorescence or qPCR) or induced to differentiate. For differentiation, SCs were 
incubated for 7 days in differentiation medium (DM) (DMEM (Gibco) containing 2% horse serum, 0.5% chicken 
embryo extract.
Transfections. Plasmid transfections of C2C12 cells were directly performed in DM by using Lipofectamine 
3000 Reagent (ThermoFisher Scientific) following manufacturer’s instructions.
Lipofectamine RNAiMAX transfection reagent (ThermoFisher Scientific) was used for short RNA molecule 
(siRNAs, mimic miRNAs, anti miRNAs, LNAs) transfections. In protocols of myoblast growth, 5500 cells/cm2 
were reverse-transfected with 20 nM of short RNA molecules and collected at different time points (from 24 up 
to 72 hours) for further analysis. In differentiation protocols, 2 × 105 cells were reverse-transfected with 60 nM of 
LNAs or siRNAs and the day after media was replaced by DM.
Anti-miR-23a-3p (AM10644), anti-miR-23b-3p (AM10711), mirvana miRna mimic hsa-miR-23a-3p 
(MC10644), mirvana miRna mimic has-miR-23b-3p (MC10711), silencer pre-designed siRNA anti Txnrd1 
(184264), silencer negative control siRNA (AM4611) were purchased from Ambion (Life technologies) and 
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used at a final concentration ranging from 10 to 25 nM. Has-miR-23 mircury LNA microRNA family inhibitor 
(450025) was purchased from Exiqon.
Three different siRNAs targeting TrxR1 in C2C12 were assayed. A similar effect on myf5 and pax7 gene 
expression was observed by comparing siRNA N°1 with N°2, although the siRNA N°1 displayed a higher effi-
ciency in depleting TrxR1 expression (Supplementary Fig. 3a and b). Then we decided to choose the siRNA N°1 
from now, on named TrxR1 siRNA, in the following experiments.
Plasmid constructs. The mouse cDNA sequence of thioredoxin reductase 1 (cytoplasmic isoform 2) open 
reading frame was amplified by PCR using the following primers: Fw sense-5′aatgcggccgccaaaagctgccaacaatgaa-3′ 
and Rv antisense-5′cagctcgaggccttcctgaacttcacctg-3′. The amplified product was cloned into the NotI and XhoI 
sites of pcDNA3.1(+) vector to generate the p-TrxR1 plasmid.
The TrxR1 3′UTR sequence was amplified by PCR from human genomic DNA using the primer Fw sense-
5′cagctcgaggttaagccccagtgtggatg-3′ and Rv antisense 5′aatgcggccgcagtaagaaggcacacgtgg-3′ and cloned into XhoI 
and NotI sites of psicheckTM-2 vector (Promega) (psi-wt).
The mutated versions of psi-wt in miR-23 binding sites were obtained by Site-directed mutagenesis. For psi 
mut1 generation, psi wt plasmid was amplified by a couple of primers carrying the miR-23 mutation in site 
1 (Fw-sense 5′cacaggtggacggcaaggattttcatttaaaaacc-3′, Rv-antisense 5′ggtttttaaatgaaaatccttgccgtccacctgtg-
3′). After DpnI (New England Biolabs) digestion, the newly synthetized plasmid was transformed into com-
petent E. coli cells (Library Efficiency DH5α competent cells; ThermoFisher Scientific). Psi-mut1-2 was 
generated from the amplification of psi-mut1 with primers harbouring miR-23 site 2 mutation (Fw-sense- 
5′caaaacaatgtgaaacattaaaattaaaaggcat-3′, Rv-sense-5′gccttttaattttaatgtttgccagtgttttg-3′).
The correct nucleotide sequence of amplified products were verified by sequencing of all the generated 
constructs.
Protein extraction and Immunoblot analysis. Cells and tissue samples were lysed in RIPA buffer 
(150 mM NaCl, 50 mM tris-HCl pH8, 1 mM EDTA, 1%NP40, 0.25% sodium deoxycholate, 0.1% SDS), supple-
mented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich). The determination of protein con-
centration was measured by colorimetric assay using the pierce BCA protein assay kit.
For the immunoblot analysis, an equal amount of proteins (20–30 µg) was resolved in SDS- polyacrylamide 
gels (10–12%) and transferred onto PVDF membranes (Amersham). Saturated membranes with 5% non fat dry 
milk in PBS- Tween (0, 01%) were incubated over-night with specific primary antibodies. The immunoreac-
tive protein bands were detected by incubation with horseradish peroxidase-conjugated secondary goat anti 
rabbit (Millipore) or goat anti mouse (Sigma-Aldrich) antibodies. The western blot images were acquired on a 
ImageQuant LAS 4000 (GEHC) and quantified by ImageJ software.
The following antibodies were purchased from Santa Cruz Biotechnology: myogenin (sc-576) cyclin D1 (sc-
718), TrxR1 (sc-20147), β-actin (sc-47778), MyHC (sc-20641) and p21(sc-397). GAPDH (MAB 374) antibody 
was purchased from Millipore.
RNA extraction and RT-qPCR analysis. Total RNA extraction was performed by using Tri-Reagent 
(Sigma) according to the manufacturer’s instructions.
For gene expression experiments, the reverse transcription (RT) and qPCR steps were conducted in the same 
reaction well by using power SYBR green RNA-to-CT 1 step kit (ThermoFisher Scientific), following manufac-
turer’s guidelines.
Specific primers were used: Myogenin sense-5′gaccctacaggtgcccacaa-3′, antisense-5′acatatcctccaccgtgatgct-3′; 
Cyclin D1 sense-5 ′cgtggcctctaagatgaagg-3 ′ ,  antisense-5 ′ tgttctcatccgcctctggc-3 ′ ;  p21 sense-
5′cggtggaactttgacttcgt-3′, antisense-5′cagggcagaggaagtactgg-3′; Myf5 sense-5′ggctggtcactgcctcatgt-3′, antisense
-5′cttgcgtcgatccatggtagt-3′; Pax7 sense-5gccctcagtgagttcgattagc’-3′, antisense-5′tccttcctcatcgtcctctttc-3′; 
Cyclophilin A sense-5′gtcaaccccaccgtgttctt-3′, antisense-5′ctgctgtctttgggaccttgt-3′.
TaqMan method was employed for microRNA expression analysis. Briefly, 10 ng of total RNA was 
reverse-transcribed using TaqMan microRNA reverse transcription kit (Applied Biosystems, 4366596) follow-
ing manufacturer’s instructions. Then 1.3 µl of each miR-specific cDNA was submitted to PCR amplification by 
using Taqman universal PCR master mix II (Applied Biosystems, 4440044). The following TaqMan microRNA 
assays were used as probes: hsa-miR-23a (000399), hsa-miR-23b (000400), hsa-miR-206 (000510) and U6 snRNA 
(001973).
The comparative cycle threshold (ΔΔCt) method was used to analyze the relative expression levels using 
cyclophilin A or U6 snRNA as internal controls.
Luciferase reporter assay. C2C12 cells were transfected with psi-wt, psi-mut1 or psimut1-2 constructs 
by using Lipofectamine 2000 transfection reagent (ThermoFisher Scientific). After 24 hours, differentially trans-
fected cells were detached, adjusted to a concentration of 35.000 cells/ml and reverse-transfected with mimic 
miR-23a and miR-23b alone or together, or with a synthetic scramble-sequence miRNA. 24 hours after plating, 
luciferase’s activity was measured by using Dual luciferase reporter assay system protocol (Promega), following 
manufacturer’s recommendations. The values reported in the graphic represent the ratio between renilla and 
firefly activities.
In silico prediction for miRNA binding sites. Bioinformatic search for miR-23 a and b binding sites in 
3′UTR of TrxR1 was performed by using TargetScanHuman 7.0 (www.targetscan.org).
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Cell growth assay. 3 × 104 reverse-transfected cells/well were seeded in a 96-well plate. After 24, 48 and 
72 hours, cell viability was measured using Cell titer aqueous assay (Promega) with MTS tetrazolium following 
manufacturer’s instructions. Four independent experiments were performed in triplicate.
Cytofluorimetric analysis. C2C12 cells were collected and fixed in EtOH 70%. After washing, samples were 
incubated with RNAse A (0.5 mg/ml) for 15 min. Propidium Iodide (PI) was then added at the final concentration 
of 20 µg/ml for 15 min at 37 °C. Cytofluorimetric analysis was performed on three independent experiment by 
using Facscalibur. Redox-blotting Trx-1 redox state in myoblasts during proliferation and differentiation (D1-D5) 
was analysed as previously described46–48 with minor modifications. To determine the proportions of Trx-1 in 
the reduced and oxidized forms, cells were resuspended in lysis buffer (50 mM Tris/Cl, pH 8.3; 3 mM EDTA; 
6 M Guanidine HCl; 0.5% Triton X-100; 1% protease inhibitor) containing 5 mM iodoacetic acid (IAA) at 37 °C 
for 30 minutes in the dark. Cell lysates were collected and filtered using a protein desalting spin column (Pierce) 
to remove excess IAA. Eluates were then diluted in 5× native and non-reducing sample buffer and separated 
by native polyacrylamide gel electrophoresis (6% stacking gel, 15% resolving gel). Gels were electroblotted to 
polyvinylidene difluoride membrane and probed for Trx-1 using anti-Trx-1 primary antibody (1:2000; Abcam) 
followed by a horseradish peroxidase-conjugated anti-rabbit secondary antibody. Bands corresponding to Trx-1 
were detected using the CCD camera of a FujiFilm LAS-4000 analyser.
Immunofluorescence analysis. For immunofluorescence analysis, muscle cells were fixed with 4% formal-
dehyde and permeabilized with 0.2% Triton X-100. To avoid unspecific binding, muscle cells were first blocked 
with a solution containing 6 ng/ml IgG from goat serum or BSA 5% in PBS. Dilutions of the following primary 
antibodies were incubated for 1–2 hours at RT in protocols relative to SCs: mouse anti-MyHC (1:200; MF20, 
MAB447), rabbit anti-TrxR1 (1:100; SC-20147). Specimens were then incubated with Alexa Fluor 488-conjugated 
anti-mouse IgG (H + L) or Alexa Fluor 594-conjugated anti-mouse IgG (H + L) secondary antibodies (Life 
Technology, 1:500) for 1 hour at RT. In C2C12 myoblasts and differentiated myotubes the anti-MyHC antibody 
(sc-20641) (1:300) or rabbit anti-TrxR1 were incubated overnight at 4 °C and the Alexa Fluor 488-conjugated 
anti-rabbit IgG (H + L) was used as secondary antibody (1:500). Hoechst dye (0.1 mg/ml) or DAPI (0.5 mg/ml) 
were added for the last 10 min to stain nuclei. Slides were mounted in Mowiol 4–88 reagent (Calbiochem) and 
images were taken using a Leica inverted microscope. Images (20X) were saved as TIFF files and Photoshop 
(Adobe) was used for composing panels.
Fusion Index. To evaluate myogenic differentiation, a fusion index was calculated to indicate myotube fusion. 
Fluorescent images of random fields were captured with 20X magnification. For each experimental condition, 
total number of nuclei and number of nuclei incorporated into the myotubes were counted. Fusion index was cal-
culated as the percentage of nuclei incorporated into myotubes (defined as containing at least two nuclei) relative 
to the total number of nuclei.
Statistical Analysis. Statistical analysis was performed using GraphPad Prism 5.03 and p values were 
calculated using the unpaired t test. Statistically significant differences are marked with asterisks in the fig-
ures (*p < 0.05; **p < 0.01; ***p < 0.001). All results represent the means ± SEM of at least three independent 
experiments.
Ethics statement. Animal experiments were performed according to protocol number 809_2015PR, follow-
ing the Institutional guidelines of the Fondazione Santa Lucia and the approval of the Ethical Committee.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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